Mouse Monoclonal WT1 Antibody

The Wilms' tumor 1 (WT1) gene, initially identified as a tumor suppressor in Wilms' tumor (a pediatric kidney cancer), encodes a zinc-finger transcription factor critical for embryonic development and cellular homeostasis. Despite its tumor-suppressive role in nephroblastoma, WT1 is aberrantly overexpressed in various malignancies, including acute leukemias, breast cancer, and mesothelioma, where it often acts as an oncogene. WT1 antibodies are tools designed to detect the WT1 protein, enabling both research and clinical applications. In diagnostics, WT1 immunohistochemistry aids in distinguishing mesothelial tumors (e.g., mesothelioma) from carcinomas or sarcomas, while in hematopathology, it helps identify leukemic blast cells. Therapeutically, WT1 has emerged as a target for immunotherapy due to its tumor-associated expression. WT1-derived peptides or mRNA vaccines, alongside adoptive T-cell therapies (e.g., CAR-T), are under investigation to harness immune responses against WT1-expressing cancers. However, challenges persist, including WT1's variable expression across tumor types and its presence in some normal tissues, necessitating careful interpretation of antibody-based assays. Ongoing research focuses on optimizing WT1-targeted strategies and understanding its dual role in tumorigenesis, balancing its potential as a biomarker and therapeutic target.